2invest AG

Latest Results (05.02.2026):

Summary — 2invest AG, Q4 2020 (financial year 2020): 2invest AG's annual report for the financial year ended 31 December 2020 shows a strong swing to profitability driven by the sale of its proteomics & immunology business. The company reported a net profit of EUR 55.0 million for FY2020 (versus a net loss of EUR 32.8 million in 2019), driven mainly by a EUR 68.4 million net gain related to the Abcam transaction. The balance sheet was materially strengthened (total assets EUR 85.6m; equity EUR 84.5m) and the company has moved to a new strategic position as an investment company following a December 2020 spin‑off of genomics/DNA operations.

Key earnings

Net profit for FY2020: EUR 55.0 million (2019: net loss EUR 32.8m). Reported revenue was negligible (EUR 69k) — the earnings swing is almost entirely due to other operating income of EUR 68.4m from the Abcam sale.

Major transactions driving results

Sale to Abcam: proteomics & immunology businesses sold (transaction price noted EUR 120m cash); net gain reported ~EUR 68.4m. Spin‑off: genomics & DNA businesses transferred to 4basebio UK Societas (effective registration 8 Dec 2020); 2invest AG retained ~30% stake and booked an investment of ~EUR 4.5m.

Balance sheet & liquidity

Total assets at 31.12.2020: EUR 85.6m. Cash and cash equivalents: EUR 47.2m. Listed securities: EUR 19.1m. Escrow cash (security for warranties): EUR 14.4m (held until release expected 1 Jan 2022). Equity: EUR 84.5m (very high solvency).

Cash flow and financing

Cash flow from operations: negative EUR 7.8m (one‑offs and settlement of intercompany items). Investing cash inflow: EUR +63.8m (mainly Abcam proceeds). Financing cash outflow: EUR -8.9m (share buybacks and repayments net of conversion proceeds). Cash at year‑end rose from EUR 0.1m to EUR 47.2m.

One‑off charges and adjustments

Restructuring / spin‑off related expenses: EUR 9.7m (including capital injections into subsidiaries prior to spin‑off). Other operating expenses rose to EUR 12.0m in 2020, largely reflecting these one‑time items. Financial result was EUR -1.25m (interest and similar expenses).

Corporate changes & capital measures

Strategic shift: company is transitioning to an investment company focused on investing proceeds from Abcam in (primarily) listed securities. Capital reduction and share consolidation (9:1) and name change to 2invest AG were approved around Jan–Mar 2021 (reported in the FY2020 disclosures). Share buyback activity reduced equity by ~EUR 9.7m; convertible exercises and other capital moves increased equity by several million.

Audit & governance

Annual financial statements and management report audited by Ernst & Young with an unqualified (clean) opinion. Supervisory Board and Management Board carried out multiple corporate governance steps (board changes, creation of audit committee) during 2020.

Outlook & risks

Management highlights high uncertainty for 2021 (COVID‑19 related and market risks) but considers the company's liquidity position adequate. Key risks going forward are market/price volatility on investments, interest/credit and currency effects, and the operational concentration of a single board member.